A
Alcista
Alcista · 25%BWAY
$14.03
Precio del escenario
$12.030
+0.040 (+0.33%)Al cierre
Loading chart…
- Máximo
- 12.190
- Apertura
- 11.840
- Precio medio ponderado por volumen
- 11.99
- Volumen
- 74.40K
- Capitalización
- 100.32M
- Mínimo
- 11.735
- Importe
- 891.69K
- EV/EBITDA, TTM
- 31.43
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Análisis de IA of Brainsway Ltd (BWAY)
ComprarBrainsway Ltd is a good buy right now due to its current price of $11.44, which is significantly below the analyst price target of $19, suggesting a potential upside of 66%. Additionally, the company has shown strong revenue growth, with a 35% increase in the latest quarter, and a gross margin of 74.62%, indicating solid profitability. The main risk is the RSI of 35.51, which suggests the stock may be oversold and could face short-term volatility.
Métricas de valoración
El PER previsto actual de Brainsway Ltd (BWAY) es 17.92, frente a su media de 5 años de 42.62.
Escenarios de precio de Alphio AI para BWAY
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con BWAY en cartera
Cronología de eventos
Noticias
7.510-19NewsfilterBrainsWay Partners with IPMG to Enhance Mental Health Treatments
- 8.510-13Newsfilter
BrainsWay Expands Medical Policy Coverage for SWIFT TMS Protocol
- 9.009-08Newsfilter
BrainsWay Announces Pilot Study Results on Depression Treatment
- 9.008-27Newsfilter
BrainsWay Publishes New Data on Depression Treatment
- 9.508-12Newsfilter
BrainsWay Reports 35% Revenue Growth in Q2 2026
Preguntas frecuentes sobre BWAY, respondidas por Alphio AI
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
Brainsway Ltd is a good buy right now due to its current price of $11.44, which is significantly below the analyst price target of $19, suggesting a potential upside of 66%. Additionally, the company has shown strong revenue growth, with a 35% increase in the latest quarter, and a gross margin of 74.62%, indicating solid profitability. The main risk is the RSI of 35.51, which suggests the stock may be oversold and could face short-term volatility.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.